{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:35:52Z","timestamp":1740116152180,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health Commisson of Hebei Province","award":["20200693"],"award-info":[{"award-number":["20200693"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>To evaluate the immunogencity and safety for three immunization schedules of inactivated poliovirus vaccine (IPV) and bivalent oral poliovirus vaccine (bOPV) for providing a basis for further optimization of the polio sequential immunization schedule. To obtain immunogenicity data and to active surveillance the occurrence of adverse events following immunization (AEFI), healthy infants \u2265 2 months of age were randomly chosen in Hebei Province, and were divided into three groups to be vaccinated with IPV-bOPV-bOPV(Group a), IPV-IPV-bOPV(Group b) and IPV-IPV-IPV(Group c) at 2, 3 and 4 months of age respectively. AEFI cases related to poliomyelitis vaccines in Hebei province by passive surveillance from January 1, 2018 to December 31, 2022 were obtained from national adverse event following immunization surveillance system (NAEFISS). After basic immunization with polio vaccine, the positive conversion rate of neutralizing antibodies of types I, II and III were all &gt; 97.00% and the positive rates were all &gt; 98.00%, the geometric mean titer (GMT) was significantly higher than that before basic immunization, the GMT level of neutralizing poliovirus antibody after basic immunization was the highest in type I, followed by type III, and the lowest in type II. A total of 16 AEFI cases (2.52%) were reported by active surveillance, and 2903 AEFI cases (1.40%) were reported by passive surveillance. AEFI reported by both monitoring modalities were dominated by fever of common vaccine reactions. No rare serious adverse reactions like VAPP etc. were monitored and the overall regression was positive. All three immunization schedules for polio vaccine have demonstrated good immunogenicity and safety when administered to healthy populations.<\/jats:p>","DOI":"10.1038\/s41598-025-89852-x","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T11:47:45Z","timestamp":1740052065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world based study for immunogenicity and safety for three immunization schedules of polio vaccine"],"prefix":"10.1038","volume":"15","author":[{"given":"Li","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-qing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-mian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-li","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha-sha","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"89852_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2217\/fmb.15.19","volume":"10","author":"AS Bandyopadhyay","year":"2015","unstructured":"Bandyopadhyay, A. S. et al. Polio vaccination: Past, present and future. Future Microbiol. 10, 791\u2013808. https:\/\/doi.org\/10.2217\/fmb.15.19 (2015).","journal-title":"Future Microbiol."},{"key":"89852_CR2","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1093\/infdis\/jiw574","volume":"216","author":"SH Gurung","year":"2017","unstructured":"Gurung, S. H. Experience with inactivated polio vaccine introduction and the switch from trivalent to bivalent oral polio vaccine in the World Health Organization\u2019s Western Pacific region. J. Infect. Dis. 216, S101\u2013S108. https:\/\/doi.org\/10.1093\/infdis\/jiw574 (2017).","journal-title":"J. Infect. Dis."},{"key":"89852_CR3","first-page":"640","volume":"64","author":"M Diop Ousmane","year":"2015","unstructured":"Diop Ousmane, M. et al. Update on vaccine-derived polioviruses-worldwide, January 2014\u2013March 2015. MMWR Morb. Mortal. Wkly. Rep. 64, 640\u2013646 (2015).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"89852_CR4","unstructured":"Global Polio Eradication Initiative. Polio Eradication Strategy 2022\u20132026: Delivering on a Promise. https:\/\/polioeradication.org\/gpei-strategy-2022-2026\/. Accessed 22 Feb 2022 (2021)."},{"key":"89852_CR5","doi-asserted-by":"publisher","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","volume":"65","author":"M Hampton Lee","year":"2016","unstructured":"Hampton Lee, M. et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine-worldwide, 2016. MMWR Morb. Mortal. Wkly. Rep. 65, 934\u2013938 (2016).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"89852_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.21037\/atm-20-2537","volume":"9","author":"T Zhao","year":"2021","unstructured":"Zhao, T. et al. Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann. Transl. Med. 9, 253. https:\/\/doi.org\/10.21037\/atm-20-2537 (2021).","journal-title":"Ann. Transl. Med."},{"key":"89852_CR7","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S1473-3099(19)30738-8","volume":"20","author":"H He","year":"2020","unstructured":"He, H. et al. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: An open-label, randomised, controlled trial. Lancet Infect. Dis. 20, 1071\u20131079 ( (2020).","journal-title":"Lancet Infect. Dis."},{"key":"89852_CR8","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1016\/j.vaccine.2021.08.065","volume":"39","author":"K Zaman","year":"2021","unstructured":"Zaman, K. et al. Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial. Vaccine 39, 5814\u20135821. https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.065 (2021).","journal-title":"Vaccine"},{"key":"89852_CR9","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1016\/j.vaccine","volume":"32","author":"D Liu","year":"2015","unstructured":"Liu, D. et al. Surveillance of adverse events following immunization in China: Past, present, and future. Vaccine 32, 4041\u20134046. https:\/\/doi.org\/10.1016\/j.vaccine (2015).","journal-title":"Vaccine"},{"key":"89852_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.13200\/j.cnki.cjb.003687","volume":"35","author":"S Haoyu","year":"2022","unstructured":"Haoyu, S. et al. Advances in development and application of inactivated poliomyelitis vaccine made from Sabin strain. Chin. J. Biol. 35, 897\u2013906. https:\/\/doi.org\/10.13200\/j.cnki.cjb.003687 (2022).","journal-title":"Chin. J. Biol."},{"key":"89852_CR11","unstructured":"World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, October 2017-conclusions and recommendations. Wkly. Epidemiol. Rec. 92, 729\u2013748 (2017)."},{"key":"89852_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1586\/14760584","volume":"15","author":"J Garon","year":"2016","unstructured":"Garon, J. et al. Polio endgame: The global switch from tOPV to bOPV. Expert Rev. Vaccines 15, 693\u2013708. https:\/\/doi.org\/10.1586\/14760584 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"89852_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3760\/cma.j.issn.0253-9624","volume":"52","author":"Y Hui","year":"2018","unstructured":"Hui, Y. et al. Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV(I+III)in different dosage forms. Chin. J. Prev. Med. 52, 43\u201349. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-9624 (2018).","journal-title":"Chin. J. Prev. Med."},{"key":"89852_CR14","first-page":"874","volume":"28","author":"L Qian","year":"2016","unstructured":"Qian, L. et al. A meta-analysis on immunogenicity of one dose or two dose salk strain inactivated poliovirus vaccine among children under seven years. Prev. Med. 28, 874\u2013878 (2016).","journal-title":"Prev. Med."},{"key":"89852_CR15","doi-asserted-by":"publisher","first-page":"2050106","DOI":"10.1080\/21645515.2022.2050106","volume":"18","author":"S Gao","year":"2022","unstructured":"Gao, S. et al. Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants. Hum. Vaccines Immunother. 18, 2050106 (2022).","journal-title":"Hum. Vaccines Immunother."},{"key":"89852_CR16","doi-asserted-by":"publisher","unstructured":"Bonnet, M. C. et al. World wide experience with inactivated poliovirus vaccine. Vaccine 26, 4978\u20134983. https:\/\/doi.org\/10.1080\/21645515.2022.2050106 (2008).","DOI":"10.1080\/21645515.2022.2050106"},{"key":"89852_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41541-024-00831-1","volume":"9","author":"T Zhao","year":"2024","unstructured":"Zhao, T. et al. Immune persistence after different polio sequential immunization schedules in Chinese infants. npj Vaccines 9, 50. https:\/\/doi.org\/10.1038\/s41541-024-00831-1 (2024).","journal-title":"npj Vaccines"},{"key":"89852_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.19914\/j.CJVI.2022041","volume":"28","author":"Z Lina","year":"2022","unstructured":"Lina, Z. et al. Surveillance of adverse events following immunization in China, 2020. Chin. J. Vaccines Immun. 28, 208\u2013218. https:\/\/doi.org\/10.19914\/j.CJVI.2022041 (2022).","journal-title":"Chin. J. Vaccines Immun."},{"key":"89852_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3969\/j.issn.1006-3110.2020.11.005","volume":"27","author":"S Li","year":"2020","unstructured":"Li, S. et al. Monitoring on safety of three types of poliomyelitis vaccines in Hebei Province. Pract. Prev. Med. 27, 1299\u20131303. https:\/\/doi.org\/10.3969\/j.issn.1006-3110.2020.11.005 (2020).","journal-title":"Pract. Prev. Med."},{"key":"89852_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.19914\/j.cjvi.2017.04.005","volume":"23","author":"F Simei","year":"2017","unstructured":"Simei, F. et al. Comparison of immunization safety of 4 kinds of polio vaccines in Jilin Province. Chin. J. Vaccines Immun. 23, 379\u2013382. https:\/\/doi.org\/10.19914\/j.cjvi.2017.04.005 (2017).","journal-title":"Chin. J. Vaccines Immun."},{"key":"89852_CR21","first-page":"4382","volume":"46","author":"Z Min","year":"2019","unstructured":"Min, Z. et al. Adverse events following immunization for poliomyelitis vaccine in Jiangxi Province, 2017\u20132018. Mod. Prev. Med. 46, 4382\u20134385 (2019).","journal-title":"Mod. Prev. Med."},{"key":"89852_CR22","first-page":"465","volume":"24","author":"H Ying","year":"2018","unstructured":"Ying, H. et al. Adverse events following immunization for poliomyelitis vaccine in Guangxi, 2016\u20132017. Appl. Prev. Med. 24, 465\u2013467 (2018).","journal-title":"Appl. Prev. Med."},{"key":"89852_CR23","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.20043\/j.cnki.MPM.202306111","volume":"50","author":"L Yake","year":"2023","unstructured":"Yake, L. et al. Surveillance and analysis of suspected abnormal reaction of polio vaccine in Shaanxi Province from 2020 to 2022. Mod. Prev. Med. 50, 3991\u20133994. https:\/\/doi.org\/10.20043\/j.cnki.MPM.202306111 (2023).","journal-title":"Mod. Prev. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89852-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89852-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89852-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T22:30:16Z","timestamp":1740090616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89852-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89852"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89852-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of the Hebei Provincial Center for Disease Control and Prevention (IRB(S)2018-009).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"6185"}}